By Finance Pulse in LLY —

Eli Lilly's Zepbound Approval Boosts Stock

Eli Lilly's shares rise 1.6% after FDA approval of Zepbound for sleep apnea, marking a 34% increase YTD. Explore Eli Lilly's success in the weight-loss market.

A sleek illustration of Eli Lilly's Zepbound packaging, with a subtle upward arrow in the background
Eli Lilly's Zepbound Approval Boosts Stock

Eli Lilly's stock rose due to FDA approval of Zepbound for sleep apnea, gaining 1.6% at midday Monday and about 34% year-to-date.

Source